{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:36:48Z","timestamp":1782963408351,"version":"3.54.5"},"reference-count":76,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/10428194.2024.2408646","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T10:45:04Z","timestamp":1727952304000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement"],"prefix":"10.1080","volume":"66","author":[{"given":"MS","family":"Ebraheem","sequence":"first","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"M.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05058-5"},{"key":"e_1_3_4_4_1","unstructured":"Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms [Internet]. Bethesda (MD): National Cancer Institute; 2023. [cited 2024 March 29]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/multiple-myeloma."},{"key":"e_1_3_4_5_1","volume-title":"Drugs approved for multiple myeloma and other plasma cell neoplasms 2024","author":"National Cancer Institute","year":"2023","unstructured":"National Cancer Institute. Drugs approved for multiple myeloma and other plasma cell neoplasms 2024. Bethesda, Maryland, USA: National Cancer Institute; 2023."},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9"},{"key":"e_1_3_4_11_1","unstructured":"A study to compare the efficacy and safety of Idecabtagene Vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06045806."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936220.68605.8b"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-023-00044-8"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V18.6.202166"},{"key":"e_1_3_4_16_1","unstructured":"Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with newly diagnosed multiple myeloma as maintenance therapy following autologous stem cell transplantation. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05243797."},{"key":"e_1_3_4_17_1","unstructured":"Study with elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma after transplant. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05317416."},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.12.007"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01890-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179866"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056147"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146210"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160173"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.36_suppl.439572"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2186480"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970364.16259.0e"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967688.12579.64"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970624.05231.6a"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162733"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177735"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189506"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185175"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.8019"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33171"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.14283\/jfa.2019.25"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09980-9"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0272-0"},{"issue":"9","key":"e_1_3_4_46_1","first-page":"924","article-title":"Non-secretory myeloma: a clinician\u2019s guide","volume":"27","author":"Lonial S","year":"2013","unstructured":"Lonial S, Kaufman JL. Non-secretory myeloma: a clinician\u2019s guide. Oncology (Williston Park). 2013;27(9):924\u2013928, 930.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.20"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.06.003"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.675"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.010"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00527-y"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8499"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25819"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647636"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00785-y"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.022178"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.1718"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1231720"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02199-2"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3113"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26010"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8030"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17945"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780471462422.eoct342"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00408-4"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3544"},{"key":"e_1_3_4_72_1","unstructured":"FDA. Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics guidance for industry."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02399"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.12.002"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2364"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970520.05307.aa"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2408646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T18:11:36Z","timestamp":1735841496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2408646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/10428194.2024.2408646"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2408646","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}